| Dismissing the value of serological testing seems like a self-serving move. Such tests are immediately of very high value because they allow us to understand immunity to Covid-19, and to actually validate the estimates of cases amongst those who haven’t sought treatment. These are both of huge value regardless of the percentage of the US population estimate to have previously contracted Covid-19. By all means market your test which seems like an awesome contribution, but please don’t do so by devaluing other important tools. [edit: the parent post has been edited to be less dismissive without acknowledgement since I made this comment] [edit: looks like I’m wrong about the post being edited. Sorry for that. I stand by everything else I say here: Serological tests are useful and needed right now, not at some future stage. It’s not hard to google to verify this, and it’s irresponsible to downplay the value of a test we need now.] |
By the way, as a company, we really don't have much to gain from this test. If it does not get adopted, we'll go back to building our core business which has been growing 100% quarter over quarter. We have poured resources into the current development, because it is the right thing to do. No investor in our Series B round will take into account any non-recurring sell-almost-at-cost revenues that we get from a once-in-a-century pandemic.